| Bioactivity | IRAK4-IN-27 (Compound 22) is a potent, selective inhibitor of IRAK4, with IC50 of 8.7 nM. IRAK4-IN-27 inhibits cell growth, and promotes apoptosis in MYD88 L265P diffuse large B-cell lymphoma (DLBCL) cell line. IRAK4-IN-27 can be used for DLBCL study[1]. |
| Invitro | IRAK4-IN-27 (Compound 22, 72 h) 对 MYD88 L265P DLBCL 细胞株 (OCI-LY10, IC50 = 0.248 μM)和 MYD88 野生型细胞株 (U2932, IC50 = 1.251 μM, 和 GM00637, IC50 = 1.520 μM) 均表现出抗增殖活性[1]。IRAK4-IN-27 (0.5 μM 和 1 μM, 24 和 48 h) 诱导 OCI-LY10 细胞凋亡[1]。IRAK4- in -27 (0.03-3 μM) 抑制 OCI-LY10 细胞中 IRAK4 磷酸化和下游信号通路[1]。IRAK4-IN-27 (0.1 μM 和 0.2 μM, 48 h) 联合 Ibrutinib (HY-10997) 抑制 OCI-LY10 细胞生长，诱导细胞凋亡[1]。 0 --> IRAK4-IN-27 相关抗体: Apoptosis Analysis[1] Cell Line: |
| Name | IRAK4-IN-27 |
| Formula | C23H22N6O3 |
| Molar Mass | 430.46 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chen Y, synthesis and pharmacological evaluation of 2,3-dihydrobenzofuran IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma. Eur J Med Chem. 2023;256:115453. |